SDMA Is Moving Into Routine Chemistry Panels. Here Is What the Clinical Data Actually Says.

IDEXX announced this week that SDMA will be built directly into Catalyst CLIPs, the point-of-care chemistry profiles most practices run as part of routine wellness and sick patient workups, beginning in June 2026 for customers in the United States and Canada. The integration means SDMA will now be part of the standard in-house panel rather than a separate order.

Why Early Detection of CKD Matters

Chronic kidney disease is one of the most common conditions in companion animal medicine. The numbers are substantial: CKD affects an estimated 1 in 3 cats and 1 in 10 dogs over their lifetime. Despite that prevalence, CKD is frequently unrecognized in its early stages. Not because veterinarians are not looking for it, but because the biomarker most commonly used to detect it has a significant blind spot.

Creatinine, the standard renal marker on most chemistry panels, does not typically become elevated until up to 75% of kidney function has already been lost. By the time creatinine flags a problem, the disease is not early anymore.

SDMA, symmetric dimethylarginine, behaves differently. Peer-reviewed studies have demonstrated that SDMA can identify changes in kidney function with as little as 25% functional loss. That gap between 25% and 75% is the clinical window where intervention has the most impact. Dietary modification, blood pressure management, phosphorus restriction, and monitoring can meaningfully slow disease progression in that window rather than simply manage its consequences.

The International Renal Interest Society, which sets the global standard for staging and managing CKD in companion animals, recognizes SDMA as a key biomarker for evaluating kidney function in pets.

What the Data Shows on Panel Performance

The argument for including SDMA on routine chemistry panels is not just about the individual biomarker. It is about what happens to diagnostic yield when you add it to an existing panel.

According to data from IDEXX, adding SDMA to in-house chemistry panels identifies on average 30% more clinically significant renal changes than creatinine alone in both dogs and cats. That figure comes from internal IDEXX data, which is worth noting as a limitation. Independent validation of in-house panel performance data is always preferable to manufacturer-reported outcomes. The underlying performance characteristics of SDMA as a biomarker, however, are supported by peer-reviewed literature across multiple institutions.

Since IDEXX introduced the SDMA test in 2015, approximately 119 million SDMA patient tests have been performed globally, the majority through reference laboratories. The move to integrate it into point-of-care Catalyst panels represents a scale shift. Previously it was a test ordered by clinicians who were already thinking about kidney disease. Now it runs automatically as part of every routine panel, surfacing renal concerns before the clinical picture gives a reason to look for them.

The Renal Diet Study Worth Knowing About

A study published in the May 2026 issue of the Journal of the American Veterinary Medical Association adds relevant context to the early detection conversation. The study found that cats with early-stage CKD treated with a veterinary therapeutic renal diet experienced slower disease progression and improved survival compared to cats not receiving dietary intervention.

The implication for clinical practice is direct: earlier detection of CKD only improves outcomes if it leads to earlier intervention. A biomarker that catches disease at 25% functional loss is most valuable when the practice has a protocol for what happens next. A conversation about diet, a recheck schedule, a monitoring plan. SDMA on a routine panel creates the detection opportunity. The clinical response to that detection is what determines whether patients actually benefit.

The integration of SDMA into routine in-house chemistry panels reflects a broader direction in companion animal diagnostics. The goal is moving the detection window earlier so that intervention can happen when it is still most effective. The clinical data supporting SDMA as an early renal biomarker is substantive and peer-reviewed. The practical question for each practice is whether the detection capability translates into a clinical workflow that acts on early findings consistently and communicates them to clients in a way that drives appropriate follow-up.

‍ ‍

The Catalyst SDMA integration is available beginning June 2026 for US and Canada customers. For more information visit idexx.com.

Vet Candy covers clinical news and diagnostics for 50,000 plus veterinary professionals. This article is based on an IDEXX press release and peer-reviewed references cited therein. myvetcandy.com